Findings of Research Misconduct, 77128-77129 [2022-27316]
Download as PDF
<![CDATA[
77128
Federal Register / Vol. 87, No. 241 / Friday, December 16, 2022 / Notices
ESTIMATED ANNUALIZED BURDEN TABLE OVER THREE YEARS
Average
burden per
response
(in hours)
Total burden
hours
Number of respondents
Private sector companies, SLTT, Trade
groups and associations, NGOs, Manufacturers, distributors, Academia, Healthcare
delivery providers/facilities, Public, USG
Supply chain inventory holders, Biopharmaceutical industry, Biotechnology development companies, Communities, GPOs,
standards development organizations, logistics, third party contractors, purchasing
organizations, professional associations/societies, Mixed cross-sector audience, labor
unions, workforce training providers, organizations, state and local workforce boards.
32800 (Form: Informed consent) ...................
32800 (Form: Demographics standardized
questionnaire with decision logic allowing
some questions to be omitted).
1
1
5/60
15/60
2734
8200
6000(Form: Cognitive questionnaire) .............
6600(Form: Formative interviews and focus
groups).
10200 (Form: Town halls and public meetings).
1000 (Form: Supply chain questionnaires) ....
6000 (Form: Knowledge-based questionnaires).
3000 (Form: Interviews and focus groups) ....
1
2
8
4
48000
52800
2
8
163200
156
1
30/60
30/60
78000
3000
1
1
3000
........................
........................
358,934
Total .........................................................
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2022–27262 Filed 12–15–22; 8:45 am]
BILLING CODE 4150–37–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY:
ACTION:
Office of the Secretary, HHS.
Notice.
Findings of research
misconduct have been made against
Alice C. Chang, Ph.D. (formerly named
Chun-Ju Chang) (Respondent), who was
an Associate Professor of Basic Medical
Sciences, College of Veterinary
Medicine, Purdue University (PU).
Respondent engaged in research
misconduct in research supported by
U.S. Public Health Service (PHS) funds,
specifically National Cancer Institute
(NCI), National Institutes of Health
(NIH), grants P30 CA023168 and R37
CA215087. The administrative actions,
including debarment for a period of ten
(10) years, were implemented beginning
on December 7, 2022, and are detailed
below.
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
Number
responses per
respondent
Type of respondent
FOR FURTHER INFORMATION CONTACT:
Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity,
VerDate Sep<11>2014
20:05 Dec 15, 2022
Jkt 259001
.........................................................................
1101 Wootton Parkway, Suite 240,
Rockville, MD 20852, (240) 453–8200.
SUPPLEMENTARY INFORMATION: Notice is
hereby given that the Office of Research
Integrity (ORI) has taken final action in
the following case:
Alice C. Chang, Ph.D., Purdue
University: Based on the report of an
investigation conducted by PU and
additional analysis conducted by ORI in
its oversight review, ORI found that Dr.
Alice C. Chang (formerly named ChunJu Chang), former Associate Professor of
Basic Medical Sciences, College of
Veterinary Medicine, PU, engaged in
research misconduct in research
supported by U.S. Public Health Service
(PHS) funds, specifically National
Cancer Institute (NCI), National
Institutes of Health (NIH), grants P30
CA023168 and R37 CA215087.
ORI found that Respondent engaged
in research misconduct by knowingly,
intentionally, or recklessly falsifying
and/or fabricating data included in the
following sixteen (16) grant applications
submitted for PHS funds:
• R21 CA191797–01, ‘‘Targeting
miR–200c for early detection of
aggressive breast cancer,’’ submitted to
NCI, NIH, on 02/17/2014.
• R21 CA194474–01, ‘‘The role of
miRNA regulated-cell polarity
machinery in breast cancer stem cell
fate decision,’’ submitted to NCI, NIH,
on 06/19/2014.
• R03 CA198606–01, ‘‘Targeting cell
polarity machinery to exhaust breast
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
cancer stem cell pool,’’ submitted to
NCI, NIH, on 10/28/2014 (funded).
• R01 CA205940–01, ‘‘Epigenetic
regulation governing ATRA-mediated
cellular programming,’’ submitted to
NCI, NIH, on 06/04/2015.
• R01 CA208325–01, ‘‘Epigenetic
mechanism underlying retinoic acid
resistance in breast cancer stem cells,’’
submitted to NCI, NIH, on 10/05/2015.
• R01 CA208325–01A1, ‘‘Epigenetic
mechanism underlying retinoic acid
resistance in tumor stem cells,’’
submitted to NCI, NIH, on 11/07/2016.
• R21 CA215908–01, ‘‘Targeting
EMT-induced mitochondrial
heterogeneity in breast cancer,’’
submitted to NCI, NIH, on 06/24/2016.
• R01 CA211063–01, ‘‘The role of
mitochondrial regulation in directing
the cancer stem cell fate,’’ submitted to
NCI, NIH, on 01/28/2016.
• R01 CA215087–01, ‘‘Targeting
metformin-directed stem cell fate in
triple negative breast cancer,’’ submitted
to NCI, NIH, on 06/03/2016.
• R37 CA215087–01A1, ‘‘Targeting
metformin-directed stem cell fate in
triple negative breast cancer,’’ submitted
to NCI, NIH, on 03/06/2017 (funded).
• R01 CA226951–01, ‘‘(PQ11) Role of
DHA in directing luminal differentiation
and therapy response in triple-negative
breast cancer,’’ submitted to NCI, NIH,
on 06/22/2017.
• R01 CA231940–01, ‘‘Regulation of
Tet2 in programming mammary stem
cell fate,’’ submitted to NCI, NIH, on 10/
05/2017.
E:\FR\FM\16DEN1.SGM
16DEN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 241 / Friday, December 16, 2022 / Notices
• R01 CA231940–01A1, ‘‘Regulation
of Tet2 in programming mammary stem
cell fate,’’ submitted to NCI, NIH, on 06/
26/2018.
• R01 CA233941–01, ‘‘DHA directs
epigenetic programming in triplenegative breast cancer,’’ submitted to
NCI, NIH, on 02/05/2018.
• R01 GM121775–01, ‘‘The role of
Tet2 regulation in directing mammary
stem cell fate,’’ submitted to the
National Institute of General Medical
Sciences (NIGMS), NIH, on 02/05/2016.
• R35 GM124972–01, ‘‘Novel role of
microRNA in directing stem cell fate
decision,’’ submitted to NIGMS, NIH, on
11/04/2016.
Specifically, ORI found that
Respondent knowingly, intentionally, or
recklessly falsified and/or fabricated
data from the same mouse models or
cell lines by reusing the data, with or
without manipulation, to represent
unrelated experiments from different
mouse models or cell lines with
different treatments in three hundred
eighty-four (384) figure panels in sixteen
(16) grant applications.
In addition, ORI found that
Respondent engaged in research
misconduct by knowingly,
intentionally, or recklessly falsifying
and/or fabricating data included in two
(2) PHS-supported published papers.
Respondent neither admits nor denies
ORI’s findings with respect to the two
(2) published papers:
• Chang CC, Wu MJ, Yang JY,
Camarillo IG, Chang CJ. Leptin-STAT3–
G9a signaling promotes obesitymediated breast cancer progression.
Cancer Res. 2015 Jun 1;75(11):2375–86.
doi: 10.1158/0008–5472.CAN–14–3076.
• Wu MJ, Kim MR, Chen YS, Yang JY,
Chang CJ. Retinoic acid directs breast
cancer cell state changes through
regulation of TET2–PKCz pathway.
Oncogene 2017 Jun 1;36(22):3193–206.
doi: 10.1038/onc.2016.467.
Specifically, ORI found that
Respondent intentionally, knowingly, or
recklessly falsified and/or fabricated:
• confocal image data for generation,
differentiation, and drug sensitivity of
cancer stem cells (CSC) in mouse
models and cell lines by reusing the
data, with or without manipulation, and
relabeling them to represent different
experiments in fifty-four (54) figure
panels included in fifteen (15) grant
applications;
• Western blot and co-IP blot images
for different protein expression in
different mouse models and cell lines by
reusing the images, with or without
manipulation, and relabeling them to
represent different experiments in
eighty-one (81) figure panels in thirteen
(13) grant applications;
VerDate Sep<11>2014
20:05 Dec 15, 2022
Jkt 259001
• figures, charts, and graphs reporting
gene expression related results for the
global or tissue-related gene expression
in mouse models and cell lines with
drug treatments by reusing them, with
or without manipulation, and relabeling
them to represent different experiments
in one hundred nineteen (119) figure
panels in fifteen (15) grant applications
and two (2) published papers;
• figures, charts, and graphs about
cellular experiment related results for
different mouse models and cell lines by
reusing them, with or without
manipulation, and relabeling them to
represent different experiments in fortytwo (42) figure panels in thirteen (13)
grant applications;
• photomicrographs for different
results from different mouse models and
cell lines by reusing them, with or
without manipulation, and relabeling
them to represent different experiments
in eighty-five (85) figure panels in
fifteen (15) grant applications;
• CSC frequency (xenograft tumor
formation) data reporting different
results from either mouse models or cell
lines by reusing and relabeling the same
data to represent different experiments
in three (3) figure panels in three (3)
grant applications.
Dr. Chang entered into a Voluntary
Exclusion Agreement (Agreement) and
voluntarily agreed to the following:
(1) Respondent will exclude herself
voluntarily for a period of ten (10) years
beginning on December 7, 2022 (the
‘‘Exclusion Period’’) from any
contracting or subcontracting with any
agency of the United States Government
and from eligibility for or involvement
in nonprocurement or procurement
transactions referred to as ‘‘covered
transactions’’ in 2 CFR parts 180 and
376 (collectively the ‘‘Debarment
Regulations’’).
(2) During the Exclusion Period,
Respondent will exclude herself
voluntarily from serving in any advisory
or consultant capacity to PHS including,
but not limited to, service on any PHS
advisory committee, board, and/or peer
review committee.
(3) Respondent will request that the
following papers be corrected:
• Cancer Res. 2015 Jun 1;
75(11):2375–86.
• Oncogene 2017 Jun 1; 36(22):3193–
206.
Respondent will copy ORI and the
Research Integrity Officer at PU on the
correspondence with the journal(s).
Dated: December 13, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity,
Office of the Assistant Secretary for Health.
[FR Doc. 2022–27316 Filed 12–15–22; 8:45 am]
BILLING CODE 4150–31–P
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
77129
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel HHS–NIH–CDC–SBIR PHS
2020–1 Phase II: Antiviral drugs to cure
chronic hepatitis B virus infection (Topic 84)
Date: January 18, 2023.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health 5601 Fishers Lane, Room 3F36
Rockville, MD 20892, (Virtual Meeting).
Contact Person: Noto K. Dutta, Ph.D.,
Scientific Review Officer, Scientific Review
Program Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health 5601
Fishers Lane, Room 3F36, Rockville, MD
20852, 240–669–2857 noton.dutta@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: December 12, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27285 Filed 12–15–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
E:\FR\FM\16DEN1.SGM
16DEN1
]]>Agencies
[Federal Register Volume 87, Number 241 (Friday, December 16, 2022)]
[Notices]
[Pages 77128-77129]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-27316]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Findings of research misconduct have been made against Alice
C. Chang, Ph.D. (formerly named Chun-Ju Chang) (Respondent), who was an
Associate Professor of Basic Medical Sciences, College of Veterinary
Medicine, Purdue University (PU). Respondent engaged in research
misconduct in research supported by U.S. Public Health Service (PHS)
funds, specifically National Cancer Institute (NCI), National
Institutes of Health (NIH), grants P30 CA023168 and R37 CA215087. The
administrative actions, including debarment for a period of ten (10)
years, were implemented beginning on December 7, 2022, and are detailed
below.
FOR FURTHER INFORMATION CONTACT: Wanda K. Jones, Dr.P.H., Acting
Director, Office of Research Integrity, 1101 Wootton Parkway, Suite
240, Rockville, MD 20852, (240) 453-8200.
SUPPLEMENTARY INFORMATION: Notice is hereby given that the Office of
Research Integrity (ORI) has taken final action in the following case:
Alice C. Chang, Ph.D., Purdue University: Based on the report of an
investigation conducted by PU and additional analysis conducted by ORI
in its oversight review, ORI found that Dr. Alice C. Chang (formerly
named Chun-Ju Chang), former Associate Professor of Basic Medical
Sciences, College of Veterinary Medicine, PU, engaged in research
misconduct in research supported by U.S. Public Health Service (PHS)
funds, specifically National Cancer Institute (NCI), National
Institutes of Health (NIH), grants P30 CA023168 and R37 CA215087.
ORI found that Respondent engaged in research misconduct by
knowingly, intentionally, or recklessly falsifying and/or fabricating
data included in the following sixteen (16) grant applications
submitted for PHS funds:
R21 CA191797-01, ``Targeting miR-200c for early detection
of aggressive breast cancer,'' submitted to NCI, NIH, on 02/17/2014.
R21 CA194474-01, ``The role of miRNA regulated-cell
polarity machinery in breast cancer stem cell fate decision,''
submitted to NCI, NIH, on 06/19/2014.
R03 CA198606-01, ``Targeting cell polarity machinery to
exhaust breast cancer stem cell pool,'' submitted to NCI, NIH, on 10/
28/2014 (funded).
R01 CA205940-01, ``Epigenetic regulation governing ATRA-
mediated cellular programming,'' submitted to NCI, NIH, on 06/04/2015.
R01 CA208325-01, ``Epigenetic mechanism underlying
retinoic acid resistance in breast cancer stem cells,'' submitted to
NCI, NIH, on 10/05/2015.
R01 CA208325-01A1, ``Epigenetic mechanism underlying
retinoic acid resistance in tumor stem cells,'' submitted to NCI, NIH,
on 11/07/2016.
R21 CA215908-01, ``Targeting EMT-induced mitochondrial
heterogeneity in breast cancer,'' submitted to NCI, NIH, on 06/24/2016.
R01 CA211063-01, ``The role of mitochondrial regulation in
directing the cancer stem cell fate,'' submitted to NCI, NIH, on 01/28/
2016.
R01 CA215087-01, ``Targeting metformin-directed stem cell
fate in triple negative breast cancer,'' submitted to NCI, NIH, on 06/
03/2016.
R37 CA215087-01A1, ``Targeting metformin-directed stem
cell fate in triple negative breast cancer,'' submitted to NCI, NIH, on
03/06/2017 (funded).
R01 CA226951-01, ``(PQ11) Role of DHA in directing luminal
differentiation and therapy response in triple-negative breast
cancer,'' submitted to NCI, NIH, on 06/22/2017.
R01 CA231940-01, ``Regulation of Tet2 in programming
mammary stem cell fate,'' submitted to NCI, NIH, on 10/05/2017.
[[Page 77129]]
R01 CA231940-01A1, ``Regulation of Tet2 in programming
mammary stem cell fate,'' submitted to NCI, NIH, on 06/26/2018.
R01 CA233941-01, ``DHA directs epigenetic programming in
triple-negative breast cancer,'' submitted to NCI, NIH, on 02/05/2018.
R01 GM121775-01, ``The role of Tet2 regulation in
directing mammary stem cell fate,'' submitted to the National Institute
of General Medical Sciences (NIGMS), NIH, on 02/05/2016.
R35 GM124972-01, ``Novel role of microRNA in directing
stem cell fate decision,'' submitted to NIGMS, NIH, on 11/04/2016.
Specifically, ORI found that Respondent knowingly, intentionally,
or recklessly falsified and/or fabricated data from the same mouse
models or cell lines by reusing the data, with or without manipulation,
to represent unrelated experiments from different mouse models or cell
lines with different treatments in three hundred eighty-four (384)
figure panels in sixteen (16) grant applications.
In addition, ORI found that Respondent engaged in research
misconduct by knowingly, intentionally, or recklessly falsifying and/or
fabricating data included in two (2) PHS-supported published papers.
Respondent neither admits nor denies ORI's findings with respect to the
two (2) published papers:
Chang CC, Wu MJ, Yang JY, Camarillo IG, Chang CJ. Leptin-
STAT3-G9a signaling promotes obesity-mediated breast cancer
progression. Cancer Res. 2015 Jun 1;75(11):2375-86. doi: 10.1158/0008-
5472.CAN-14-3076.
Wu MJ, Kim MR, Chen YS, Yang JY, Chang CJ. Retinoic acid
directs breast cancer cell state changes through regulation of TET2-
PKC[zeta] pathway. Oncogene 2017 Jun 1;36(22):3193-206. doi: 10.1038/
onc.2016.467.
Specifically, ORI found that Respondent intentionally, knowingly,
or recklessly falsified and/or fabricated:
confocal image data for generation, differentiation, and
drug sensitivity of cancer stem cells (CSC) in mouse models and cell
lines by reusing the data, with or without manipulation, and relabeling
them to represent different experiments in fifty-four (54) figure
panels included in fifteen (15) grant applications;
Western blot and co-IP blot images for different protein
expression in different mouse models and cell lines by reusing the
images, with or without manipulation, and relabeling them to represent
different experiments in eighty-one (81) figure panels in thirteen (13)
grant applications;
figures, charts, and graphs reporting gene expression
related results for the global or tissue-related gene expression in
mouse models and cell lines with drug treatments by reusing them, with
or without manipulation, and relabeling them to represent different
experiments in one hundred nineteen (119) figure panels in fifteen (15)
grant applications and two (2) published papers;
figures, charts, and graphs about cellular experiment
related results for different mouse models and cell lines by reusing
them, with or without manipulation, and relabeling them to represent
different experiments in forty-two (42) figure panels in thirteen (13)
grant applications;
photomicrographs for different results from different
mouse models and cell lines by reusing them, with or without
manipulation, and relabeling them to represent different experiments in
eighty-five (85) figure panels in fifteen (15) grant applications;
CSC frequency (xenograft tumor formation) data reporting
different results from either mouse models or cell lines by reusing and
relabeling the same data to represent different experiments in three
(3) figure panels in three (3) grant applications.
Dr. Chang entered into a Voluntary Exclusion Agreement (Agreement)
and voluntarily agreed to the following:
(1) Respondent will exclude herself voluntarily for a period of ten
(10) years beginning on December 7, 2022 (the ``Exclusion Period'')
from any contracting or subcontracting with any agency of the United
States Government and from eligibility for or involvement in
nonprocurement or procurement transactions referred to as ``covered
transactions'' in 2 CFR parts 180 and 376 (collectively the ``Debarment
Regulations'').
(2) During the Exclusion Period, Respondent will exclude herself
voluntarily from serving in any advisory or consultant capacity to PHS
including, but not limited to, service on any PHS advisory committee,
board, and/or peer review committee.
(3) Respondent will request that the following papers be corrected:
Cancer Res. 2015 Jun 1; 75(11):2375-86.
Oncogene 2017 Jun 1; 36(22):3193-206.
Respondent will copy ORI and the Research Integrity Officer at PU
on the correspondence with the journal(s).
Dated: December 13, 2022.
Wanda K. Jones,
Acting Director, Office of Research Integrity, Office of the Assistant
Secretary for Health.
[FR Doc. 2022-27316 Filed 12-15-22; 8:45 am]
BILLING CODE 4150-31-P
